Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
37
IOVA Quote, Financials, Valuation and Earnings
Last price:
$3.78
Seasonality move
:
-8.68%
Day range:
$3.76 - $4.03
52-week range:
$1.64 - $5.63
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.27x
P/B ratio:
2.29x
Volume:
9.7M
Avg. volume:
18.1M
1-year change:
5.6%
Market cap:
$1.6B
Revenue:
$263.5M
EPS (TTM):
-$1.12
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
|
$81M | -$0.18 | 60.64% | -61.17% | $9.00 |
|
AXGN
Axogen, Inc.
|
$59.9M | $0.10 | 18.96% | 933.4% | $40.56 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | -1.07% | 39.86% | $14.90 |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$32.3M | -$0.53 | -- | -54.03% | $34.00 |
|
LNTH
Lantheus Holdings, Inc.
|
$367M | $1.17 | -4.81% | 20.76% | $91.38 |
|
OFIX
Orthofix Medical, Inc.
|
$218.7M | $0.42 | -0.19% | -78.6% | $17.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
|
$3.89 | $9.00 | $1.6B | -- | $0.00 | 0% | 5.27x |
|
AXGN
Axogen, Inc.
|
$30.94 | $40.56 | $1.6B | -- | $0.00 | 0% | 6.50x |
|
INFU
InfuSystem Holdings, Inc.
|
$9.83 | $14.90 | $198.7M | 31.19x | $0.00 | 0% | 1.44x |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$16.56 | $34.00 | $837M | -- | $0.00 | 0% | 57.45x |
|
LNTH
Lantheus Holdings, Inc.
|
$80.45 | $91.38 | $5.2B | 23.89x | $0.00 | 0% | 3.60x |
|
OFIX
Orthofix Medical, Inc.
|
$12.03 | $17.25 | $482.9M | -- | $0.00 | 0% | 0.58x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.61% | -2.426 | 4.4% | 2.74x |
|
AXGN
Axogen, Inc.
|
34.42% | -0.343 | 4.38% | 3.08x |
|
INFU
InfuSystem Holdings, Inc.
|
29.89% | 4.137 | 13.48% | 1.31x |
|
KALV
KalVista Pharmaceuticals, Inc.
|
94.33% | -1.978 | 45.9% | 6.99x |
|
LNTH
Lantheus Holdings, Inc.
|
36.38% | -2.085 | 14.5% | 2.35x |
|
OFIX
Orthofix Medical, Inc.
|
31.18% | -0.044 | 33.76% | 1.34x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
|
$34.1M | -$73.5M | -50.85% | -54.64% | -84.79% | -$61.9M |
|
AXGN
Axogen, Inc.
|
$44.4M | -$9.8M | -8.61% | -13.75% | -16.31% | $1.1M |
|
INFU
InfuSystem Holdings, Inc.
|
$19.9M | $3.7M | 7.84% | 11.83% | 10.25% | $7M |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$12.5M | -$46.1M | -97.51% | -243.25% | -336.33% | -$54.8M |
|
LNTH
Lantheus Holdings, Inc.
|
$240.9M | $77.6M | 13.39% | 20.75% | 19.07% | $76M |
|
OFIX
Orthofix Medical, Inc.
|
$153.3M | $1.2M | -13.92% | -19.94% | 0.53% | $17.6M |
Iovance Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns IOVA or AXGN?
Axogen, Inc. has a net margin of -82.92% compared to Iovance Biotherapeutics, Inc.'s net margin of -21.96%. Iovance Biotherapeutics, Inc.'s return on equity of -54.64% beat Axogen, Inc.'s return on equity of -13.75%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.39.31% -$0.18 $748M AXGNAxogen, Inc.74.13% -$0.28 $196.5M -
What do Analysts Say About IOVA or AXGN?
Iovance Biotherapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 131.36%. On the other hand Axogen, Inc. has an analysts' consensus of $40.56 which suggests that it could grow by 31.08%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Axogen, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Axogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 3 0 AXGNAxogen, Inc.7 0 0 -
Is IOVA or AXGN More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.690, which suggesting that the stock is 30.977% less volatile than S&P 500. In comparison Axogen, Inc. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.752%.
-
Which is a Better Dividend Stock IOVA or AXGN?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Axogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or AXGN?
Iovance Biotherapeutics, Inc. quarterly revenues are $86.7M, which are larger than Axogen, Inc. quarterly revenues of $59.9M. Iovance Biotherapeutics, Inc.'s net income of -$71.9M is lower than Axogen, Inc.'s net income of -$13.2M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Axogen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 5.27x versus 6.50x for Axogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.5.27x -- $86.7M -$71.9M AXGNAxogen, Inc.6.50x -- $59.9M -$13.2M
-
Which has Higher Returns IOVA or INFU?
InfuSystem Holdings, Inc. has a net margin of -82.92% compared to Iovance Biotherapeutics, Inc.'s net margin of 5.62%. Iovance Biotherapeutics, Inc.'s return on equity of -54.64% beat InfuSystem Holdings, Inc.'s return on equity of 11.83%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.39.31% -$0.18 $748M INFUInfuSystem Holdings, Inc.54.99% $0.10 $81.8M -
What do Analysts Say About IOVA or INFU?
Iovance Biotherapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 131.36%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.90 which suggests that it could grow by 51.58%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 3 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is IOVA or INFU More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.690, which suggesting that the stock is 30.977% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.665, suggesting its more volatile than the S&P 500 by 66.488%.
-
Which is a Better Dividend Stock IOVA or INFU?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or INFU?
Iovance Biotherapeutics, Inc. quarterly revenues are $86.7M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.2M. Iovance Biotherapeutics, Inc.'s net income of -$71.9M is lower than InfuSystem Holdings, Inc.'s net income of $2M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 31.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 5.27x versus 1.44x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.5.27x -- $86.7M -$71.9M INFUInfuSystem Holdings, Inc.1.44x 31.19x $36.2M $2M
-
Which has Higher Returns IOVA or KALV?
KalVista Pharmaceuticals, Inc. has a net margin of -82.92% compared to Iovance Biotherapeutics, Inc.'s net margin of -361.39%. Iovance Biotherapeutics, Inc.'s return on equity of -54.64% beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.39.31% -$0.18 $748M KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M -
What do Analysts Say About IOVA or KALV?
Iovance Biotherapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 131.36%. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $34.00 which suggests that it could grow by 105.31%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than KalVista Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 3 0 KALVKalVista Pharmaceuticals, Inc.7 0 0 -
Is IOVA or KALV More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.690, which suggesting that the stock is 30.977% less volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.351, suggesting its less volatile than the S&P 500 by 135.123%.
-
Which is a Better Dividend Stock IOVA or KALV?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or KALV?
Iovance Biotherapeutics, Inc. quarterly revenues are $86.7M, which are larger than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. Iovance Biotherapeutics, Inc.'s net income of -$71.9M is lower than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 5.27x versus 57.45x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.5.27x -- $86.7M -$71.9M KALVKalVista Pharmaceuticals, Inc.57.45x -- $13.7M -$49.5M
-
Which has Higher Returns IOVA or LNTH?
Lantheus Holdings, Inc. has a net margin of -82.92% compared to Iovance Biotherapeutics, Inc.'s net margin of 13.3%. Iovance Biotherapeutics, Inc.'s return on equity of -54.64% beat Lantheus Holdings, Inc.'s return on equity of 20.75%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.39.31% -$0.18 $748M LNTHLantheus Holdings, Inc.59.21% $0.82 $1.7B -
What do Analysts Say About IOVA or LNTH?
Iovance Biotherapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 131.36%. On the other hand Lantheus Holdings, Inc. has an analysts' consensus of $91.38 which suggests that it could grow by 13.59%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Lantheus Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 3 0 LNTHLantheus Holdings, Inc.9 2 0 -
Is IOVA or LNTH More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.690, which suggesting that the stock is 30.977% less volatile than S&P 500. In comparison Lantheus Holdings, Inc. has a beta of -0.106, suggesting its less volatile than the S&P 500 by 110.622%.
-
Which is a Better Dividend Stock IOVA or LNTH?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lantheus Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Lantheus Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or LNTH?
Iovance Biotherapeutics, Inc. quarterly revenues are $86.7M, which are smaller than Lantheus Holdings, Inc. quarterly revenues of $406.8M. Iovance Biotherapeutics, Inc.'s net income of -$71.9M is lower than Lantheus Holdings, Inc.'s net income of $54.1M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Lantheus Holdings, Inc.'s PE ratio is 23.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 5.27x versus 3.60x for Lantheus Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.5.27x -- $86.7M -$71.9M LNTHLantheus Holdings, Inc.3.60x 23.89x $406.8M $54.1M
-
Which has Higher Returns IOVA or OFIX?
Orthofix Medical, Inc. has a net margin of -82.92% compared to Iovance Biotherapeutics, Inc.'s net margin of -1.01%. Iovance Biotherapeutics, Inc.'s return on equity of -54.64% beat Orthofix Medical, Inc.'s return on equity of -19.94%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.39.31% -$0.18 $748M OFIXOrthofix Medical, Inc.69.7% -$0.06 $653.9M -
What do Analysts Say About IOVA or OFIX?
Iovance Biotherapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 131.36%. On the other hand Orthofix Medical, Inc. has an analysts' consensus of $17.25 which suggests that it could grow by 43.39%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Orthofix Medical, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Orthofix Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 3 0 OFIXOrthofix Medical, Inc.2 2 0 -
Is IOVA or OFIX More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.690, which suggesting that the stock is 30.977% less volatile than S&P 500. In comparison Orthofix Medical, Inc. has a beta of 0.750, suggesting its less volatile than the S&P 500 by 25.028%.
-
Which is a Better Dividend Stock IOVA or OFIX?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orthofix Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Orthofix Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or OFIX?
Iovance Biotherapeutics, Inc. quarterly revenues are $86.7M, which are smaller than Orthofix Medical, Inc. quarterly revenues of $219.9M. Iovance Biotherapeutics, Inc.'s net income of -$71.9M is lower than Orthofix Medical, Inc.'s net income of -$2.2M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Orthofix Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 5.27x versus 0.58x for Orthofix Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.5.27x -- $86.7M -$71.9M OFIXOrthofix Medical, Inc.0.58x -- $219.9M -$2.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
43
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Sell
50
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Sell
40
GDXU alert for Mar 19
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 18.95% over the past day.
Sell
43
GDXD alert for Mar 19
MicroSectors Gold Miners -3X Inverse Leveraged ETN [GDXD] is up 19.01% over the past day.
Sell
38
RKLB alert for Mar 19
Rocket Lab Corp. [RKLB] is up 1.53% over the past day.
